Agree that Brilacidin is now the leading drug in terms of clinical development. Don't forget about the QIDP designation. The five-year extension of market exclusivity is very significant, although we might not see the benefits until Phase 3 is up and running.
When I first invested in CTIX, I knew it's going to be a decade long investment. This year will be year #4. These minor delays don't affect me at all. If an investor does not share the long-term vision of the CEO, then he/she should not be in the stock long-term.
Market Data 
Markets 
AI
